|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Endometriosis - New Therapies Near Market while More Innovative Targets Still Needed
Datamonitor, Dec 2009, Pages: 147
Endometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Symptoms include severe chronic pelvic pain and infertility. Endometriosis affects over 17 million women across the seven major markets. Nonetheless, its complex symptomatology contributes to difficult diagnosis and unclear etiology obstructs the discovery of disease modifying approaches.
Scope
- Analysis of endometriosis etiology, symptomology, diagnosis, treatment, prevalence trends, and key unmet market needs.
- Review of the pre-clinical and clinical pipeline for new endometriosis therapies, including analysis of key R&D company strategies.
- In depth analysis of historic (200408) seven major markets and rest of the world trends with future (20092018) seven major market dynamics.
- Commercial and clinical assessment of key late-stage pipeline drugs, with opinion leader comment and region-specific sales forecasts to 2018.
Highlights of this title
Environmental factors, increased awareness and diagnosis will cause the incidence of endometriosis to increase in the seven major markets. Drugs in the market are not curative and do not provide long term pain relief yet there are only 13 agents in clinical development for the potential treatment of endometriosis.
Although contraceptives and progestogens are commonly used to treat endometriosis, these are mainly used off label. Bayer Schering will be able to use its sales and marketing resource to overcome the challenging task of convincing physicians to use its new endometriosis specific drug Visanne (dienogest) over other hormonal contraceptives.
Neurocrine's elagolix is the first oral non peptide gonadotropin releasing hormone (GnRH) antagonist. Phase II trials have shown that it is effective in treating endometriosis and does not reduce bone mineral density during 6 months therapy. This will allow the drug to become market leading in 2018.
Key reasons to purchase this title
- Analyze competitive environment at time of product launch.
- Validate internal forecasts and market potential for pipeline products.
- Identify licensing opportunities based on company portfolio and market needs.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018
Endometriosis - Global Strategic Business Report
R&D Trends: Women's Health - Investment needed to address lack of innovation
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
Women's Health Series: Endometriosis--How Will New Therapies Compare with Current Market Leaders?
Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine
Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics
Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of First Approval set to Reinvigorate Interest from Major Companies
|
|
|
|
